XTalks

DECEMBER 26, 2023

for placebo, p<0.0001) at Week 5. The New Drug Application (NDA) for KarXT in the treatment of schizophrenia in adults has recently been accepted, with a Prescription Drug User Fee Act (PDUFA) action date set for September 26, 2024. The trial revealed a statistically significant and clinically meaningful reduction of 9.6

Trials 105

Trials FDA Approval Drugs Development 105

The Pharma Data

OCTOBER 28, 2020

log10 copies/mL greater reduction with REGN-COV2 compared to placebo (combined dose groups; p<0.0001). log10 copies/mL greater reduction with REGN-COV2 compared to placebo (combined dose groups; p=0.0003). placebo; p=0.024). There was a 1.08 combined dose groups; 6.5%

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 29, 2020

The results passed the futility analysis (p<0.3 log 10 copies/mL (nominal p=0.002 for combined doses). log 10 copies/mL (nominal p=0.002 for combined doses). The primary clinical objective of this initial analysis was to determine if there was sufficient efficacy in these patients to warrant continuing the trial (i.e.,

Antibody 52

Antibody Trials Production Clinical Trials 52